Announcements from Chinese regulatory authorities or Alpha Cognition

Alpha Cognition Secures $44 Million Licensing Deal for Alzheimer's Drug Zunveyl in China, Including $6 Million Upfront

Jan 8, 2025, 01:48 PM

Alpha Cognition Inc. has announced a $44 million exclusive licensing agreement for the development and commercialization of Zunveyl, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, in China. The deal includes a $6 million upfront payment and covers regions including Asia (excluding Japan), Australia, and New Zealand. Zunveyl, also known as benzgalantamine, is anticipated to address neuroinflammation associated with Alzheimer’s disease. This agreement was made with China Medical System, as Alpha Cognition aims to expand its market presence in the Asia-Pacific region.